Table 2.
Case reports
| Study | Patient demographics | Diagnosis and baseline | Drug and dose | Outcomes |
|---|---|---|---|---|
|
| ||||
| Matsumoto 2007 | 49 years, male | CRVO-ME | Single bevacizumab 1.25 mg | At 1 m f/u, VA 20/60, CRT 199 μm |
| VA 5/400 | At 2 m f/u VA 20/400, CRT 1013 μm | |||
| CRT 871 μm | ||||
|
| ||||
| Spandau 2006 | 68 years, male | Non-ischemic CRVO-ME | Single bevacizumab 1.5 mg | At 2 m f/u, VA 20/25, CRT 217 μm |
| VA 20/200 | ||||
| CRT 662 μm | ||||
CME: cystoid macular edema
CRT: central retinal thickness
CRVO: central retinal vein occlusion
f/u: follow up
ME: macular edema
mg: milligram
VA: visual acuity
m: month